SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Icilin | 36945-98-9 | sc-201557 sc-201557A | 10 mg 50 mg | $91.00 $257.00 | 9 | |
Icilin is a selective agonist of TRPV3 channels, characterized by its unique ability to induce thermal hyperalgesia through specific binding interactions. It stabilizes the open conformation of the channel, enhancing cation influx and altering cellular excitability. The compound's hydrophobic regions interact favorably with lipid bilayers, affecting membrane fluidity and channel activation kinetics. Icilin's distinct molecular architecture allows for precise modulation of sensory signaling pathways, contributing to its unique physiological effects. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
This is a classic non-selective TRPV3 inhibitor that has been used in research to block TRPV3-mediated responses. | ||||||
HC 067047 | 883031-03-6 | sc-361204 sc-361204A | 10 mg 50 mg | $217.00 $840.00 | 9 | |
This is a selective TRPV3 inhibitor that has shown efficacy. | ||||||
LY315920 | 172732-68-2 | sc-364528 sc-364528A | 5 mg 10 mg | $315.00 $490.00 | ||
While primarily known as a phospholipase A2 inhibitor, LY315920 has also been reported to inhibit TRPV3 channels. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
While primarily known as a local anesthetic, lidocaine has been reported to inhibit TRPV3 channels, contributing to its analgesic effects. | ||||||
A-967079 | 1170613-55-4 | sc-363348 sc-363348A sc-363348B | 5 mg 25 mg 100 mg | $88.00 $372.00 $942.00 | 5 | |
Although initially developed as a TRPA1 antagonist, A-967079 has been reported to exhibit inhibitory effects on TRPV3 as well. | ||||||